Liposomal MTP-PE

Fujimaki ltoh K. , An T. , Gano JB , et al: Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A). Cancer Biother 8:307-318, 1993

Fidler U. : Targeting of immunomodulators to mononuclear phagocytes for therapy in cancer . Adv Drug Del Rev 1:69, 1988

Fidler U. , Sone S. , Fogler WE , et al: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl tripeptide . Proc Natl Acad Sci USA 78:1680, 1986

Kleinerman ES , Erickson KL , Schroit AJ , et al: Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide . Cancer Res 432010-2014, 1983

Sone S. , Utsugi T. , Tandon P. , et al: A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state. Cancer Immunol Immunother 22:191-196, 1986

Kleinerman ES , Jia SF , Griffin J. , et al: Phase II study of liposomal muramyl tripeptide in osteosarcoma: The cytokine cascade and monocyte activation following administration. J Clin Oncol 10:1310-1316, 1992

Kleinerman ES , Murray JL , Snyder JS , et al: Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine . Cancer Res 49:4665-4670, 1989

Ciba-Geigy Ltd : Guidelines for preparation of CGP 19835A lipid 1 mg or 4 mg liposomal suspension for IV infusion by gravity (package insert). Bethesda, MD: National Cancer Institute, 1993

Murray JL , Kleinerman ES , Cunningham JE , et al: Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 7:1915-1925, 1989

Urba WJ , Hartmann LC , Longo DL , et al: Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res 50:2979-2986, 1990